Vyne’s BD2-selective BET inhibitor cleared by FDA for phase I
May 7, 2024
Vyne Therapeutics Inc. has received IND clearance from the FDA allowing it to initiate a first-in-human phase Ia study of VYN-202, an oral small-molecule BD2-selective BET inhibitor for autoimmune diseases.